{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:51:33Z","timestamp":1768801893354,"version":"3.49.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.parkreldis.2020.09.022","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T22:30:16Z","timestamp":1608330616000},"page":"S28-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S1","title":["Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?"],"prefix":"10.1016","volume":"80","author":[{"given":"Peter","family":"Jenner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.20834","article-title":"The Parkinson's complex: parkinsonism is just the tip of the iceberg","volume":"59","author":"Langston","year":"2006","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.09.022_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrn.2017.91","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.09.022_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","article-title":"The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study)","volume":"30","author":"Pont-Sunyer","year":"2015","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JPD-140372","article-title":"Non-motor symptoms profile and burden in drug naive versus long-term Parkinson's disease patients","volume":"4","author":"Zis","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fnagi.2017.00301","article-title":"Parkinson's disease subtypes identified from cluster Analysis of motor and non-motor symptoms","volume":"9","author":"Mu","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.09.022_bib7","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/mds.21065","article-title":"Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered","volume":"21","author":"Braak","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib8","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/bs.irn.2017.05.015","article-title":"Personalized medicine and nonmotor symptoms in Parkinson's disease","volume":"134","author":"Titova","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.09.022_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5694\/mja17.00993","article-title":"Non-motor Parkinson disease: new concepts and personalised management","volume":"208","author":"Titova","year":"2018","journal-title":"Med. J. Aust."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.09.022_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","article-title":"Parkinson's: a syndrome rather than a disease?","volume":"124","author":"Titova","year":"1996","journal-title":"J. Neurol. Transm. (Vienna, Austria"},{"issue":"5","key":"10.1016\/j.parkreldis.2020.09.022_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.09.022_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and management of neuropsychiatric symptoms in Parkinson's disease","volume":"32","author":"Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2020.09.022_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jocn.2019.08.058","article-title":"Potential predictors of quality of life in Parkinson's Disease: sleep and mood disorders","volume":"70","author":"Palmeri","year":"2019","journal-title":"J. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2010.08.012","article-title":"Determinants of health-related quality of life in Parkinson's disease: a systematic review","volume":"17","author":"Soh","year":"2011","journal-title":"Park. Relat. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.09.022_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cns.13190","article-title":"Research progress on adenosine in central nervous system diseases","volume":"25","author":"Liu","year":"2019","journal-title":"CNS Neurosci. Ther."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets--what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mam.2016.12.002","article-title":"Pharmacological targeting of adenosine receptor signaling","volume":"55","author":"Peleli","year":"2017","journal-title":"Mol. Aspect. Med."},{"issue":"11 Suppl 6","key":"10.1016\/j.parkreldis.2020.09.022_bib18","first-page":"S44","article-title":"Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists","volume":"61","author":"Mori","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neulet.2003.08.059","article-title":"Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats","volume":"352","author":"Shindou","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B978-0-12-801022-8.00004-0","article-title":"Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease","volume":"119","author":"Mori","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0301-0082(99)00011-8","article-title":"Distribution, biochemistry and function of striatal adenosine A2A receptors","volume":"59","author":"Svenningsson","year":"1999","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0301-0082(95)00035-6","article-title":"Adenosine A2 receptor-mediated excitatory actions on the nervous system","volume":"48","author":"Sebastiao","year":"1996","journal-title":"Prog. Neurobiol."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2020.09.022_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/09084282.2011.595453","article-title":"Characteristic of cognitive decline in Parkinson's disease: a 1-year follow-up","volume":"18","author":"McKinlay","year":"2011","journal-title":"Appl. Neuropsychol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib26","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.nbd.2012.03.029","article-title":"Cognitive impairment and dementia in Parkinson's disease","volume":"46","author":"Pagonabarraga","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.09.022_bib27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","article-title":"Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment","volume":"11","author":"Svenningsson","year":"2012","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.09.022_bib29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00702-019-02003-1","article-title":"Mild cognitive impairment in Parkinson's disease","volume":"126","author":"Martinez-Horta","year":"2019","journal-title":"J. Neural. Transm."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.09.022_bib30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/mds.25853","article-title":"Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective","volume":"29","author":"Robbins","year":"2014","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/revneuro-2013-0004","article-title":"Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease","volume":"24","author":"Narayanan","year":"2013","journal-title":"Rev. Neurosci."},{"issue":"15","key":"10.1016\/j.parkreldis.2020.09.022_bib32","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1111\/bph.13180","article-title":"Adenosine A2A receptors are necessary and sufficient to trigger memory impairment in adult mice","volume":"172","author":"Pagnussat","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/B978-0-12-801022-8.00012-X","article-title":"Adenosine receptor control of cognition in normal and disease","volume":"119","author":"Chen","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.fbp.0000166825.62130.9a","article-title":"Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats","volume":"16","author":"Prediger","year":"2005","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0361-9230(01)00501-9","article-title":"Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats","volume":"55","author":"Gevaerd","year":"2001","journal-title":"Brain Res. Bull."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.09.022_bib36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1460-9568.2004.03586.x","article-title":"Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates","volume":"20","author":"Decamp","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"Pt A","key":"10.1016\/j.parkreldis.2020.09.022_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2016.07.012","article-title":"An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models","volume":"110","author":"Ko","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","article-title":"Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial","volume":"16","author":"Fernandez","year":"2010","journal-title":"Park. Relat. Disord."},{"issue":"4409","key":"10.1016\/j.parkreldis.2020.09.022_bib39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.112679","article-title":"Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey","volume":"205","author":"Brozoski","year":"1979","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00213-005-0221-2","article-title":"Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex","volume":"183","author":"Clinton","year":"2006","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-013-3158-x","article-title":"Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex","volume":"230","author":"Kadowaki Horita","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.parkreldis.2020.09.022_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-0-12-801022-8.00008-8","article-title":"Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson's disease","volume":"119","author":"Uchida","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"issue":"Pt A","key":"10.1016\/j.parkreldis.2020.09.022_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.expneurol.2016.05.040","article-title":"Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy","volume":"283","author":"Hu","year":"2016","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease--epidemiology, mechanisms and management","volume":"8","author":"Aarsland","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.09.022_bib45","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00702-019-02019-7","article-title":"Neuropsychiatric aspects of Parkinson's disease","volume":"126","author":"Nagy","year":"2019","journal-title":"J. Neural. Transm."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2020.09.022_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2006.05.030","article-title":"Quality of life and depression in Parkinson's disease","volume":"248","author":"Schrag","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-444-64012-3.00007-1","article-title":"Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics","volume":"165","author":"Butala","year":"2019","journal-title":"Handb. Clin. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.09.022_bib48","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2020.00025","article-title":"Neuropsychiatric disorders in Parkinson's disease: what do we know about the role of dopaminergic and non-dopaminergic systems?","volume":"14","author":"Dujardin","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.physbeh.2012.11.001","article-title":"The effect of unpredictable chronic mild stress on depressive-like behavior and on hippocampal A1 and striatal A2A adenosine receptors","volume":"109","author":"Crema","year":"2013","journal-title":"Physiol. Behav."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjp.0704240","article-title":"Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice","volume":"134","author":"El Yacoubi","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib52","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fphar.2018.00526","article-title":"Caffeine and selective adenosine receptor antagonists as new therapeutic tools for the motivational symptoms of depression","volume":"9","author":"Lopez-Cruz","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib53","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.neuroscience.2010.05.068","article-title":"Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism","volume":"170","author":"Nunes","year":"2010","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1124\/pr.117.015107","article-title":"The psychopharmacology of effort-related decision making: dopamine, adenosine, and insights into the neurochemistry of motivation","volume":"70","author":"Salamone","year":"2018","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jnc.14841","article-title":"The role of adenosine receptors in mood and anxiety disorders","volume":"151","author":"van Calker","year":"2019","journal-title":"J. Neurochem."},{"issue":"11","key":"10.1016\/j.parkreldis.2020.09.022_bib56","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.biopsych.2013.05.003","article-title":"Regulation of fear responses by striatal and extrastriatal adenosine A2A receptors in forebrain","volume":"75","author":"Wei","year":"2014","journal-title":"Biol. Psychiatr."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/glia.23476","article-title":"Region-specific control of microglia by adenosine A2A receptors: uncoupling anxiety and associated cognitive deficits in female rats","volume":"67","author":"Duarte","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.parkreldis.2020.09.022_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pbb.2013.10.022","article-title":"Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents","volume":"114\u2013115","author":"Yamada","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"14","key":"10.1016\/j.parkreldis.2020.09.022_bib59","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1007\/s00213-014-3454-0","article-title":"Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats","volume":"231","author":"Yamada","year":"2014","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jns.2018.11.005","article-title":"Effect of istradefylline on mood disorders in Parkinson's disease","volume":"396","author":"Nagayama","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.09.022_bib61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000341998","article-title":"Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis","volume":"11","author":"Kehagia","year":"2013","journal-title":"Neurodegener. Dis."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.nbd.2011.12.040","article-title":"Animal models of the non-motor features of Parkinson's disease","volume":"46","author":"McDowell","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/B978-0-12-801022-8.00014-3","article-title":"Roles of adenosine and its receptors in sleep-wake regulation","volume":"119","author":"Huang","year":"2014","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib64","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/164_2017_36","article-title":"Adenosine and sleep","volume":"253","author":"Lazarus","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib65","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fnins.2019.00740","article-title":"Gating and the need for sleep: Dissociable effects of adenosine A1 and A2A receptors","volume":"13","author":"Lazarus","year":"2019","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib66","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.sleep.2007.03.005","article-title":"Neurobiology of REM and NREM sleep","volume":"8","author":"McCarley","year":"2007","journal-title":"Sleep Med."},{"issue":"5316","key":"10.1016\/j.parkreldis.2020.09.022_bib67","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.276.5316.1265","article-title":"Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness","volume":"276","author":"Porkka-Heiskanen","year":"1997","journal-title":"Science"},{"issue":"11 Suppl 6","key":"10.1016\/j.parkreldis.2020.09.022_bib68","first-page":"S94","article-title":"Sleep regulation in adenosine A2A receptor-deficient mice","volume":"61","author":"Urade","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.parkreldis.2020.09.022_bib69","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nn1491","article-title":"Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine","volume":"8","author":"Huang","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"27","key":"10.1016\/j.parkreldis.2020.09.022_bib70","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1523\/JNEUROSCI.6730-10.2011","article-title":"Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens","volume":"31","author":"Lazarus","year":"2011","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib71","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41467-017-00781-4","article-title":"Slow-wave sleep is controlled by a subset of nucleus accumbens core neurons in mice","volume":"8","author":"Oishi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib72","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.29055","article-title":"Striatal adenosine A2A receptor neurons control active-period sleep via parvalbumin neurons in external globus pallidus","volume":"6","author":"Yuan","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.parkreldis.2020.09.022_bib73","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jns.2017.07.045","article-title":"Istradefylline improves daytime sleepiness in patients with Parkinson's disease: an open-label, 3-month study","volume":"380","author":"Suzuki","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib74","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2017.10.018","article-title":"The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson's disease","volume":"662","author":"Matsuura","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.09.022_bib75","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.neurobiolaging.2004.08.012","article-title":"Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors","volume":"26","author":"Prediger","year":"2005","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.parkreldis.2020.09.022_bib76","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2004.10.017","article-title":"Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats","volume":"159","author":"Prediger","year":"2005","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib77","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neulet.2004.11.049","article-title":"Modulation of short-term social memory in rats by adenosine A1 and A2A receptors","volume":"376","author":"Prediger","year":"2005","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.09.022_bib78","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.expneurol.2006.01.005","article-title":"Improved spatial recognition memory in mice lacking adenosine A2A receptors","volume":"199","author":"Wang","year":"2006","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nlm.2006.05.004","article-title":"Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain","volume":"87","author":"Gim\u00e9nez-Llort","year":"2007","journal-title":"Neurobiol. Learn. Mem."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.09.022_bib80","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1101\/lm.2136011","article-title":"Selective inactivation of adenosine A2A receptors in striatal neurons enhances working memory and reversal learning","volume":"18","author":"Wei","year":"2011","journal-title":"Learn. Mem."},{"issue":"48","key":"10.1016\/j.parkreldis.2020.09.022_bib81","doi-asserted-by":"crossref","first-page":"15100","DOI":"10.1523\/JNEUROSCI.4215-09.2009","article-title":"Genetic deletion of A2A adenosine receptors in the striatum selectively impairs habit formation","volume":"29","author":"Yu","year":"2009","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.09.022_bib82","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00213-011-2198-3","article-title":"Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists","volume":"216","author":"Randall","year":"2011","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2017.10.014","article-title":"Istradefylline reduces memory deficits in aging mice with amyloid pathology","volume":"110","author":"Orr","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnmol.2018.00235","article-title":"Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe\/PS1dE9 mouse model of alzheimer's disease","volume":"11","author":"Faivre","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib85","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/mp.2014.151","article-title":"A2A adenosine receptor deletion is protective in a mouse model of Tauopathy","volume":"21","author":"Laurent","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.09.022_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nbd.2015.03.030","article-title":"Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models","volume":"79","author":"Li","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"11","key":"10.1016\/j.parkreldis.2020.09.022_bib87","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.biopsych.2015.02.026","article-title":"Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia","volume":"78","author":"Matos","year":"2015","journal-title":"Biol. Psychiatr."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib88","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.neuroscience.2009.05.023","article-title":"Age-related spatial working memory impairment is caused by prefrontal cortical dopaminergic dysfunction in rats","volume":"162","author":"Mizoguchi","year":"2009","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.parkreldis.2020.09.022_bib89","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-006-0404-5","article-title":"Mesocortical dopamine modulation of executive functions: beyond working memory","volume":"188","author":"Floresco","year":"2006","journal-title":"Psychopharmacol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.09.022_bib90","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0893-133X(02)00290-7","article-title":"Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats","volume":"27","author":"Acquas","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.09.022_bib91","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2017.07.017","article-title":"The corticostriatal adenosine A2A receptor controls maintenance and retrieval of spatial working memory","volume":"83","author":"Li","year":"2018","journal-title":"Biol. Psychiatr."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib92","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0306-4522(01)00372-4","article-title":"Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission","volume":"107","author":"d'Alcantara","year":"2001","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib93","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuron.2007.11.023","article-title":"Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses","volume":"57","author":"Rebola","year":"2008","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/mp.2012.8","article-title":"Adenosine A2A receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation","volume":"18","author":"Batalha","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2020.09.022_bib95","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/hipo.20894","article-title":"Enhancement of AMPA currents and GluR1 membrane expression through PKA-coupled adenosine A2A receptors","volume":"22","author":"Dias","year":"2012","journal-title":"Hippocampus"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib96","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1460-9568.2011.07719.x","article-title":"Enhanced role of adenosine A2A receptors in the modulation of LTP in the rat hippocampus upon ageing","volume":"34","author":"Costenla","year":"2011","journal-title":"Eur. J. Neurosci."},{"issue":"5890","key":"10.1016\/j.parkreldis.2020.09.022_bib97","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.1160575","article-title":"Dichotomous dopaminergic control of striatal synaptic plasticity","volume":"321","author":"Shen","year":"2008","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.parkreldis.2020.09.022_bib98","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.1523\/JNEUROSCI.0034-13.2013","article-title":"Long-term depression of synaptic kainate receptors reduces excitability by relieving inhibition of the slow afterhyperpolarization","volume":"33","author":"Chamberlain","year":"2013","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.09.022_bib99","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.neuropharm.2008.01.011","article-title":"Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine","volume":"54","author":"Fontinha","year":"2008","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.09.022_bib100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1471-4159.2007.05046.x","article-title":"Adenosine A2A receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus","volume":"104","author":"Tebano","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2020.09.022_bib101","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neuropharm.2014.04.006","article-title":"Impact of in vivo chronic blockade of adenosine A2A receptors on the BDNF-mediated facilitation of LTP","volume":"83","author":"Jer\u00f3nimo-Santos","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2020.09.022_bib102","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbr.2015.02.032","article-title":"Adenosine signaling in reserpine-induced depression in rats","volume":"286","author":"Minor","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.09.022_bib103","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.pbb.2011.10.015","article-title":"The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade","volume":"100","author":"Collins","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.09.022_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.952","article-title":"Behavioral changes induced through adenosine A2A receptor ligands in a rat depression model induced by olfactory bulbectomy","volume":"8","author":"Padilla","year":"2018","journal-title":"Brain and Behavior"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020307367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020307367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:21:17Z","timestamp":1761178877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020307367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":104,"alternative-id":["S1353802020307367"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.09.022","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}